Drug intelligence / Profile preview

BSC-3301

Development stage: Preclinical
Lead developer: BiSiChem
Modality: Small Molecules
Administration: Oral

Overview

BSC-3301 is an orally bioavailable, brain-penetrant small molecule that acts as a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor. It is being developed by BiSiChem for the treatment of neurodegenerative and immune-related diseases. The drug's mechanism of action involves inhibition of RIPK1, a key mediator in cell death and inflammation pathways implicated in conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and wet age-related macular degeneration. As of the latest updates, BSC-3301 remains in preclinical development for these indications[1][2][4].

Other names: BSC 3301BSC3301BSC-3301

Targets

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on BSC-3301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSC-3301.

Explore the full profile